This was the stock's second consecutive day of gains.

Does Catalyst Pharmaceutical (CPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

What if you'd invested in Catalyst Pharmaceutical (CPRX) ten years ago? It may not have been easy to hold on to CPRX for all that time, but if you did, how much would your investment be worth today?

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Catalyst Pharmaceutical (CPRX) closed the last trading session at $24.96, gaining 0.5% over the past four weeks, but there ...

FIRDAPSE boosts Catalyst's strong Q1 2025 results, beating forecasts. With 15–20% growth projected, see why analysts rate ...

Catalyst Pharmaceuticals has announced the appointment of Dr. William T. Andrews as Chief Medical Officer, who will report to President and CEO Richard J. Daly. Dr. Andrews, who succeeds retiring ...

CORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of ...

This was the stock's second consecutive day of gains.

Catalyst Pharmaceuticals will announce Q4 and 2024 financial results on February 26, followed by a conference call on February 27. Catalyst Pharmaceuticals, Inc. announced that it will release its ...

CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical ...